Ybox-01 Update -

Recent preclinical studies (2022–2024) have expanded the therapeutic profile of YBox-01 beyond initial expectations.

3.1. Monotherapy in Triple-Negative Breast Cancer (TNBC) In xenograft models utilizing patient-derived xenografts (PDXs) of TNBC, YBox-01 demonstrated a tumor growth inhibition (TGI) rate of 68% as a monotherapy. Crucially, tumor regression was observed in subtypes exhibiting high baseline YB-1 expression, validating YB-1 as a predictive biomarker. ybox-01 update

3.2. Combination Strategies The most significant update in the YBox-01 development pipeline is its synergy with PARP inhibitors (e.g., olaparib). Preclinical data suggests that YBox-01 impairs the DNA damage repair machinery controlled by YB-1. When combined with PARP inhibitors, a potent synthetic lethality was observed in BRCA1/2 wild-type models, suggesting a potential expansion of PARP inhibitor indications to patients previously ineligible for this treatment. How to Download and Install the ybox-01 update

3.3. Pharmacokinetics and Toxicology Phase I preclinical toxicology in non-human primates indicated a favorable safety profile. YBox-01 exhibits a half-life of approximately 14 hours, allowing for convenient dosing schedules. No significant cardiotoxicity or myelosuppression was noted at therapeutic doses, a distinct advantage over current standard-of-care cytotoxics. ybox-01 update

Here is the definitive breakdown of what is inside the ybox-01 update (v3.2.1).